Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

65.60EUR
11:36am EDT
Change (% chg)

€-0.21 (-0.32%)
Prev Close
€65.81
Open
€65.76
Day's High
€66.05
Day's Low
€65.35
Volume
2,183,232
Avg. Vol
2,718,670
52-wk High
€92.97
52-wk Low
€62.88

Latest Key Developments (Source: Significant Developments)

FDA Approves Toujeo® Max Solostar®
Tuesday, 27 Mar 2018 08:03am EDT 

March 27 (Reuters) - Sanofi Sa ::FDA APPROVES TOUJEO® MAX SOLOSTAR®.SANOFI - FDA APPROVED SANOFI'S TOUJEO (INSULIN GLARGINE 300 UNITS/ML) MAX SOLOSTAR.  Full Article

Alnylam Retains Global Rights To Lumasiran, Investigational RNAi Therapeutic For Treatment Of Primary Hyperoxaluria Type 1
Monday, 12 Mar 2018 07:00am EDT 

March 12 (Reuters) - Alnylam Pharmaceuticals Inc ::ALNYLAM RETAINS GLOBAL RIGHTS TO LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1).ALNYLAM PHARMACEUTICALS INC - ‍COMPANY PLANS TO ACCELERATE DEVELOPMENT WITH PHASE 3 START IN LATE 2018​.ALNYLAM PHARMACEUTICALS INC - ‍LUMASIRAN GRANTED BREAKTHROUGH THERAPY DESIGNATION BY UNITED STATES FOOD AND DRUG ADMINISTRATION​.ALNYLAM PHARMACEUTICALS INC - ‍SANOFI GENZYME HAS DECLINED ITS OPT-IN FOR DEVELOPMENT AND COMMERCIALIZATION OF LUMASIRAN​.  Full Article

FDA To Review Dupixent® (Dupilumab) As Potential Treatment For Moderate-To-Severe Asthma
Friday, 2 Mar 2018 01:00am EST 

March 2 (Reuters) - Regeneron Pharmaceuticals Inc ::FDA TO REVIEW DUPIXENT® (DUPILUMAB) AS POTENTIAL TREATMENT FOR MODERATE-TO-SEVERE ASTHMA.‍PER PRESCRIPTION DRUG USER FEE ACT, TARGET ACTION DATE IS OCTOBER 20, 2018​.‍POTENTIAL USE OF DUPIXENT IN ASTHMA IS CURRENTLY UNDER CLINICAL DEVELOPMENT​.SAFETY AND EFFICACY FOR ‍DUPIXENT IN ASTHMA HAVE NOT BEEN FULLY EVALUATED BY ANY REGULATORY AUTHORITY​.  Full Article

Reg-Sanofi Announces Receipt Of Antitrust Clearances In Connection With The Acquisition Of Ablynx
Wednesday, 28 Feb 2018 12:21pm EST 

March 1 (Reuters) - Sanofi ::* Sanofi has received clearance from the Federal Cartel Office of Germany in accordance with the Act Against Restraints of Competition, applicable to Sanofi's proposed acquisition of Ablynx NV .  Full Article

Ablynx Announces Option Exercise By Sanofi To License Two Additional Target Combinations​
Friday, 16 Feb 2018 01:00am EST 

Feb 16 (Reuters) - ABLYNX NV ::ABLYNX ANNOUNCES OPTION EXERCISE BY SANOFI FOR TWO ADDITIONAL MULTI-SPECIFIC NANOBODY PRODUCT CANDIDATES.SANOFI HAS EXERCISED ITS OPTION TO LICENSE TWO ADDITIONAL TARGET COMBINATIONS​.‍OPTION AS PART OF RESEARCH COLLABORATION SIGNED IN JULY 2017​.‍SANOFI GAINS EXCLUSIVE GLOBAL RIGHTS TO TWO ADDITIONAL MULTI-SPECIFIC NANOBODIES AGAINST SELECTED TARGETS​.‍IN RETURN SANOFI WILL PAY ABLYNX EXERCISE FEES TOTALLING EUR 13 MILLION PLUS ADDITIONAL RESEARCH FUNDING​.‍ABLYNX HAS ALREADY RECEIVED AN UPFRONT PAYMENT TOTALLING EUR 23 MILLION.‍RECEIVED AN UPFRONT PAYMENT IS TOGETHER WITH RESEARCH FUNDING UNDER THIS COLLABORATION​.‍SANOFI WILL BE RESPONSIBLE FOR DEVELOPMENT, MANUFACTURING AND COMMERCIALISATION OF ANY PRODUCTS RESULTING FROM THIS AGREEMENT​.‍ABLYNX WILL BE ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS OF UP TO EUR 2.4 BILLION PLUS TIERED ROYALTIES​.  Full Article

Regeneron Reports Q4 Adj. Earnings Per Share $5.23
Thursday, 8 Feb 2018 06:30am EST 

Feb 8 (Reuters) - Regeneron Pharmaceuticals Inc ::REGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS.Q4 NON-GAAP EARNINGS PER SHARE $5.23.Q4 GAAP EARNINGS PER SHARE $1.50.REGENERON PHARMACEUTICALS - Q4 GAAP NET INCOME PER DILUTED SHARE INCLUDES CHARGE OF $2.82/DILUTED SHARE IN CONNECTION WITH U.S. TAX REFORM LEGISLATION.SEES, IN FY 2018, SANOFI COLLABORATION REVENUE OF $450 MILLION TO $500 MILLION.Q4 EYLEA (AFLIBERCEPT) INJECTION U.S. NET SALES INCREASED 14% TO $975 MILLION VERSUS Q4 2016.SEES FY 2018 CAPITAL EXPENDITURES OF $420 MILLION TO $500 MILLION.REGENERON PHARMA - TOTAL REVENUES, WHICH INCLUDE PRODUCT REVENUES , INCREASED BY 29% TO $1.582 BILLION IN Q4.Q4 EARNINGS PER SHARE VIEW $4.53, REVENUE VIEW $1.50 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Sanofi Commences Tender Offer For Acquisition Of Bioverativ
Thursday, 8 Feb 2018 05:55am EST 

Feb 8 (Reuters) - SANOFI ::SANOFI COMMENCES TENDER OFFER FOR ACQUISITION OF BIOVERATIV INC. <<>>.TENDER OFFER TO ACQUIRE ALL OF OUTSTANDING SHARES OF COMMON STOCK OF BIOVERATIV ‍FOR $105 PER SHARE IN CASH ​.  Full Article

Sanofi CFO Refuses To Provide 2018 Outlook Excluding Recent Acquisitions Of Bioverativ, Ablynx
Wednesday, 7 Feb 2018 04:28am EST 

Feb 7 (Reuters) - Sanofi ::CFO REFUSES TO PROVIDE 2018 OUTLOOK EXCLUDING RECENT ACQUISITIONS OF BIOVERATIV, ABLYNX.CEO SAYS GROUP REMAINS “VERY COMMITTED” TO DENGVAXIA PROGRAM.CEO SAYS HAS REDUCED DIABETES AND CARDIOVASCULAR SALES STAFF BY 400 LAST YEAR IN THE U.S.CEO SAYS GROUP PLANS NO RESTRUCTURING MEASURES IN THE U.S THIS YEAR.  Full Article

Partner Therapeutics Acquires Leukine From Sanofi
Thursday, 1 Feb 2018 06:56am EST 

Feb 1 (Reuters) - Sanofi Sa ::PARTNER THERAPEUTICS (PTX) ACQUIRES LEUKINE® FROM SANOFI.PARTNER THERAPEUTICS INC - HAS ACQUIRED GLOBAL RIGHTS TO DEVELOP, MANUFACTURE, AND COMMERCIALIZE LEUKINE (SARGRAMOSTIM) FROM SANOFI.PARTNER THERAPEUTICS - IN CONNECTION WITH ACQUISITION OF LEUKINE, PTX WILL ALSO ACQUIRE A DEDICATED MANUFACTURING FACILITY IN LYNNWOOD, WASHINGTON.  Full Article

Sanofi CFO sees cost of debt to finance Ablynx acquisition around 1 pct
Monday, 29 Jan 2018 08:38am EST 

Jan 29 (Reuters) - Sanofi Chief Financial Officer Jerome Contamine says::expects cost of debt to finance Ablynx acquisition to be around 1 percent.  Full Article

Photo

WHO recommends testing before use of Sanofi's dengue vaccine

PARIS/CHICAGO The World Health Organization (WHO) said on Thursday Sanofi's vaccine against dengue should only be used after testing on individuals to assess whether they have ever been exposed to the infection.